| Issue | Title | |
| Vol 23, No 1 (2022) | Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy | Abstract HTML PDF |
| Edoardo Mannucci, Gianni Ghetti | ||
| Vol 15, No 4 (2014) | Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration | Abstract HTML PDF |
| Piergiorgio Neri, Ilir Arapi, Chiara Maria Eandi, Vittorio Pirani, Cesare Mariotti, Alfonso Giovannini | ||
| Vol 15, No 1 (2014) | Cost-effectiveness of tenofovir in the treatment of patients with chronic hepatitis B: data from literature | Abstract HTML PDF |
| Massimo Fasano, Giorgio L. Colombo, Sergio Di Matteo, Claudia Randazzo, Gioacchino Angarano, Teresa Antonia Santantonio | ||
| Vol 17, No 3 (2016) | Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy | Abstract HTML PDF |
| Gianluca De Danieli, Fabio Monari, Renzo Lazzarini, Filippo Cipriani | ||
| Vol 9, No 3 (2008) | Cost-efficacy analysis of hormonal treatments for advanced prostate cancer | Abstract PDF |
| Sergio Iannazzo, Lorenzo Pradelli | ||
| Vol 3, No 2 (2002) | Costi del trattamento con oloprazina nelle fasi iniziali della schizofrenia | Abstract PDF |
| Domenico Berardi, Maddalena Dell’Atti, Francesca Russo, Virginia Vagnini, Luca Guidi, Eric T. Edgell | ||
| Vol 6, No 2 (2005) | Costi e bisogni sanitari degli anziani non autosufficienti presso le strutture residenziali: strategie e interventi per una popolazione che invecchia | Abstract PDF |
| Marta Moro, Chiara Salvato, Gianni Terrazzani, Donatella Serraglia, Cristina Saramin, Pietro Giusti, Alessandro Chinellato | ||
| Vol 5, No 1 (2004) | Costi ed effetti di Risperidone Long Acting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia | Abstract PDF |
| Lorenzo G. Mantovani, Patrizia Berto, Anna D. Ausilio, Bart Heeg | ||
| Vol 4, No 1 (2003) | Costi sanitari di un programma vaccinale: analisi di minimizzazione dei costi | Abstract PDF |
| G. L. Colombo, A. Muzio, R. Giordani | ||
| Vol 6, No 3 (2005) | Costo/efficacia della prevenzione di infezioni alle prime vie aeree mediante un estratto batterico immunostimolante aspecifico (OM-85) | Abstract PDF |
| Orietta Zaniolo, Lorenzo Pradelli, Mario Eandi | ||
| Vol 5, No 1 (2004) | Costo-efficacia dell’amfotericina B liposomiale nella terapia dell’aspergillosi invasiva | Abstract PDF |
| Mario Eandi | ||
| Vol 2, No 1 (2001) | Costruzione di un modello decisionale per valutare la costo/efficacia delle strategie alternative nella terapia della polmonite acquisita in comunità | Abstract PDF |
| Mario Eandi | ||
| Vol 8, No 2 (2007) | Costs and efficacy ofolanzapine and risperidone in schizophrenia | Abstract PDF |
| Vittorio Mapelli | ||
| Vol 10, No 2 (2009) | Costs of diabetes in Italy | Abstract PDF |
| Orietta Zaniolo | ||
| Vol 14, No 2 (2013) | Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model | Abstract HTML PDF |
| Mario Eandi, Lorenzo Pradelli, Massimiliano Povero | ||
| Vol 9, No 1 (2008) | Cost-utility analysis of abatacept in rheumatoid arthritis in Italy | Abstract PDF |
| Simona de Portu, Lorenzo Giovanni Mantovani, Ignazio Olivieri | ||
| Vol 15, No 4 (2014) | Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients | Abstract HTML PDF |
| Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro | ||
| Vol 15, No 3 (2014) | Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy | Abstract HTML PDF |
| Craig Bennison, Stephanie Stephens, Giario Natale Conti | ||
| Vol 13, No 1 (2012) | Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? | Abstract HTML PDF |
| Jenny Alwin, Thor-Henrik Brodtkorb | ||
| Vol 1, No 1 (2000) | Creare Valore Sanitario: nuove prospettive per il management delle aziende sanitarie | Abstract PDF |
| Giorgio Donna, Salvatore Nieddu | ||
| Vol 1, No 2 (2000) | Creazione di valore sanitario e sistemi di finanziamento: il caso del dipartimento di salute mentale | Abstract PDF |
| Carmine Munizza, Salvatore Nieddu | ||
| Vol 21, No 1 (2020) | Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa | Abstract HTML PDF |
| Matteo Nicola Dario Di Minno, Lucia D'Angiolella, Paolo Angelo Cortesi, Angelo Claudio Molinari, Lorenzo Giovanni Mantovani | ||
| Vol 10, No 3 (2009) | Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery | Abstract PDF |
| Orietta Zaniolo | ||
| Vol 9, No 3 (2008) | Daptomycin (Cubicin) in patients with complicated skin or soft-tissue infections | Abstract PDF |
| Viola Sacchi | ||
| Vol 9, No 2 (2008) | Decision analytic economic paliperidone ER in relapsing schizophrenic patients in Italy | Abstract PDF |
| Patrizia Berto, Cristina Negrini, Luigi Ferrannini | ||
| Vol 17, No 2 (2016) | Demand for healthcare by the elderly in developing countries | Details HTML PDF |
| Yinka Kehinde Binuomoyo, Abimbola Oluseyi Ogunsola | ||
| Vol 12, No 2S (2011) | DENALI: il Data Warehouse di Sanità Pubblica della Regione Lombardia | Details PDF |
| Giancarlo Cesana, Carla Fornari, Virginio Chiodini, Fabiana Madotto, Luca Merlino, Lorenzo G. Mantovani | ||
| Vol 20, No 1 (2019) | Developing a Model for the Establishment of Pre-Hospital Emergency Medicine Bases in the Northern Provinces of Iran | Abstract HTML PDF |
| Azadeh Ahmadi Dashtiyan, Iravan Masoudi Asl, Leila Riahi, Mahmood Mahmoodi | ||
| Vol 14, No 4 (2013) | Direct medical costs of COPD diagnosis and treatment, Eastern vs Western European country – examples of Serbia and Belgium | Abstract HTML PDF |
| Mihajlo B Jakovljevic, Zorica Lazic, Nick Verhaeghe, Slobodan Jankovic, Olgica Gajovic, Lieven Annemans | ||
| Vol 4, No 2 (2003) | Durata e costo delle visite in medicina generale: il progetto DYSCO | Abstract PDF |
| Livio Garattini, Emanuela Castelnuovo, Davide Lanzeni, Cecilia Viscarra, DYSCO VISITE Gruppo di studio DYSCO VISITE | ||
| Vol 1, No 2 (2000) | È possibile coniugare risparmio e miglioramento nelle aziende USL? | Abstract PDF |
| Sergio Sabbatani | ||
| Vol 7, No 4 (2006) | Economic and clinical value of levofloxacin | Abstract PDF |
| Mario Eandi, Orietta Zaniolo | ||
| Vol 15, No 3 (2014) | Economic burden of Communicable and Non-communicable Diseases in Jamaica: Is our research focus where it should be? | Details HTML PDF |
| Christine Fray-Aiken | ||
| Vol 23, No 1 (2022) | Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis | Abstract HTML PDF |
| Marco Bellone, Lorenzo Pradelli, Rita Tavarozzi, Marco Ladetto, Giuliana Nepoti, Emanuele Guardalben, Daniela Ghislieri | ||
| Vol 10, No 3 (2009) | Economic crisis and consumption of medical resources in Italy | Details PDF |
| Mario Eandi | ||
| Vol 20, No 1 (2019) | Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C | Abstract HTML PDF |
| Stefano Fagiuoli, Luisa Pasulo, Franco Maggiolo, Rosaria Spinella, Paolo Del Poggio, Roberto Boldizzoni, Mariella Di Marco, Alessandro Aronica, Chiara Benedetti, Paolo Correale, Chiara Garavaglia, Carlo Nicora | ||
| Vol 10, No 2 (2009) | Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study | Abstract PDF |
| Simona de Portu, Giacomo Carteni, Andrea Belisari | ||
| Vol 7, No 3 (2006) | Economic evaluation of the CARDS study | Abstract PDF |
| Simona de Portu, Enrica Menditto, Lorenzo G. Mantovani | ||
| Vol 14, No 3 (2013) | Economic evaluation of the chronic hepatitis B treatment strategies in Italy | Abstract HTML PDF |
| Sergio Iannazzo, Barbara Coco, Maurizia Brunetto, Francesca Rossetti, Antonietta Caputo, Maria De Francesco, Ferruccio Bonino | ||
| Vol 11, No 2 (2010) | Economic evaluation of the use of saxagliptin in the treatment of type 2 diabetes in Italy | Abstract PDF |
| Marco Cristiani, Anna Citarella, Andrea Belisari, Guido Didoni, Lorenzo Giovanni Mantovani, Sabato Montella | ||
| Vol 15, No 4 (2014) | Economic impact of the use of Hyalubrix® in the treatment of hip osteoarthritis in Italy | Abstract HTML PDF |
| Alberto Migliore, Andrea Belisari, Lucia S. D'Angiolella, Emanuele Bizzi, Umberto Massafra, Prisco Piscitelli, Lorenzo Giovanni Mantovani | ||
| Vol 18, No 1 (2017) | Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre | Abstract HTML PDF |
| Angela Variola, Arianna Massella, Andrea Geccherle, Paolo Bocus, Roberto Tessari, Teresa Zuppini, Roberto Ravasio | ||
| Vol 19, No 1 (2018) | Editorial Staff Disclosure (2018) | Details HTML PDF |
| Ombretta Bandi | ||
| Vol 10, No 4 (2009) | Effectiveness and cost of treatment with maraviroc in HIV infection | Abstract PDF |
| Viola Sacchi, Lorenzo Pradelli | ||
| Vol 20, No 1 (2019) | Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations | Abstract HTML PDF |
| Orietta Zaniolo, Gianni Ghetti, Massimiliano Povero, Lorenzo Pradelli | ||
| Vol 3, No 1 (2002) | Efficienza tecnologica e produttiva delle strutture trasfusionali in Italia | Abstract PDF |
| Dante Cornago, Livio Garattini | ||
| Vol 13, No 2S (2012) | Emilia Romagna | Abstract HTML PDF |
| Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni | ||
| Vol 9, No 1S (2008) | Emilia Romagna | Abstract PDF |
| Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi | ||
| Vol 9, No 3 (2008) | Entecavir (Baraclude) in patients with chronic hepatitis B virus (HPV) infection | Abstract PDF |
| Viola Sacchi | ||
| Vol 12, No 2S (2011) | Epidemiologia, prevenzione e trattamento delle malattie cardiovascolari: evidenze dal database della medicina generale | Details PDF |
| Giampiero Mazzaglia, Alessandro Filippi, Lorenzo G. Mantovani, Gianluca Furneri, Carlo Niccolai, Jacopo Cricelli, Achille P. Caputi, Ovidio Brignoli, Claudio Cricelli | ||
| Vol 9, No 2 (2008) | Epidemiological and economic aspects of diabetes in the Campania Region, Italy | Abstract PDF |
| Simona Cammarota, Andrea Morsanutto, Enrica Menditto, Anna Citarella, Simona de Portu | ||
| Vol 9, No 4 (2008) | Epidemiology and costs of HPV infection: review of the evidence | Abstract PDF |
| Francesco Bamfi, Alessia Marocco, Stefano Capri, Mario Giovanni Sideri | ||
| Vol 18, No 1 (2017) | Equilibrium between resources and expenditure of health sector of Social Security Fund: a case study of Iran | Abstract HTML PDF |
| Azadeh Ahmadi Dashtian, Mohsen Mardali | ||
| Vol 11, No 2 (2010) | Equity of access to innovative drugs and sustainability of pharmaceutical expenditure | Details PDF |
| Mario Eandi | ||
| Vol 7, No 1 (2006) | Errata corrige: “Valutazione clinica e metabolica dell’impiego dell’insulina Lispro in pazienti con diabete mellito scompensato” | Details PDF |
| Antonio Uneddu, Tito Antonio Paolini | ||
| Vol 20, No 1 (2019) | Erratum: Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations | Abstract HTML PDF |
| [No authors listed] | ||
| Vol 13, No 3S (2012) | Essential to increase the use of generics in Europe to maintain comprehensive health care? | Abstract HTML PDF |
| Brian Godman, Marion Bennie, Christoph Baumgärtel, Ljiljana Sović-Brkičić, Thomas Burkhardt, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Vanda Markovic-Pekovic, Andrew Martin, Catherine Sermet, Peter Skiold, Menno van Woerkom, Luka Voncina, Lars L. Gustafsson | ||
| Vol 19, No 1 (2018) | Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation | Abstract HTML PDF |
| Marco Bellone, Lorenzo Pradelli, Mario Bo | ||
| Vol 12, No 1 (2011) | Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice | Abstract PDF |
| Orietta Zaniolo, Germano Bettoncelli, Giancarlo Bosio, Lorenzo Mantovani, Riccardo Pistelli, Adriano Vaghi, Marco Villa, Sergio Iannazzo, Francesco Bamfi, Vincenzo Frizzo, Roberto Walter Dal Negro | ||
| Vol 14, No 2 (2013) | European and Italian regulation on orphan medicinal products | Abstract HTML PDF |
| Roberta Joppi | ||
| Vol 7, No 1 (2006) | European health information system and cardiovascular diseases | Details PDF |
| Mario Eandi | ||
| Vol 9, No 1 (2008) | Evaluation of antimicrobial consumption in Campania Region, Italy | Abstract PDF |
| Simona Cammarota, Anna Citarella, Enrica Menditto, Simona de Portu | ||
| Vol 9, No 1 (2008) | Evaluation of health resources expenditure in two groups of psychotic patients treated with olanzapine and typical neuroleptics in a Italian Mental Health Department in Calabria Region | Abstract PDF |
| Anna Caputo, Luca Guidi, Giovanni Biricolti, Sergio Torchia | ||
| Vol 20, No 1 (2019) | Evaluation of patients treated for diabetic retinopathy: an analysis of the administrative databases of the Lazio Region | Abstract HTML PDF |
| Francesco Mennini, Lorella Lombardozzi, Alessandra Mecozzi, Paolo Sciattella | ||
| Vol 18, No 1 (2017) | Evaluation of the cost saving potential of introducing Benepali® and Flixabi® on the European and Italian markets | Abstract HTML PDF |
| Cristina Negrini, Emi Psachoulia | ||
| Vol 9, No 3 (2008) | Evolution of global drug market and amrket access | Details PDF |
| Mario Eandi | ||
| Vol 6, No 4 (2005) | Evoluzione del mercato farmaceutico nei primi nove mesi del 2005 | Details PDF |
| Mario Eandi | ||
| Vol 4, No 1S (2003) | Evoluzione storica della farmacoutilizzazione degli anti-ipertensivi in Italia (1988-1998) | Abstract PDF |
| Enrico Bologna, Pierluigi Russo, Sabrina Licata, Liliana Civalleri, Luciano Caprino | ||
| Vol 15, No 2 (2014) | Experiences of including costs of added life years in health economic evaluations in Sweden | Abstract HTML PDF |
| Laura Pirhonen, Thomas Davidson | ||
| Vol 21, No 1 (2020) | Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective | Abstract HTML PDF |
| Daniela Paola Roggeri, Ezio Zanon, Chiara Biasoli, Alessandro Roggeri | ||
| Vol 4, No 4 (2003) | Farmaci antipertensivi a confronto: costi e benefici per il paziente e la collettività | Abstract PDF |
| Francesco Vittorio Costa | ||
| Vol 2, No 4 (2001) | Farmaci orfani e malattie rare: la situazione in Italia | Abstract |
| S. Martina, C. Denti, E. Daina, L. Garattini | ||
| Vol 2, No 3 (2001) | Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento | Abstract PDF |
| S. Martina, C. Denti, L. Garattini | ||
| Vol 4, No 1S (2003) | Farmacoeconomia dei COXIB nella patologia osteoarticolare: revisione della letteratura | Abstract PDF |
| Pierluigi Russo, Luca Degli Esposti, Alessandro Capone, Ezio Degli Esposti, Luciano Caprino | ||
| Vol 8, No 2S (2007) | Farmacoeconomia e malattie cardiovascolari | Details PDF |
| Lorenzo G. Mantovani, Andrea Morsanutto, Simona De Portu | ||
| Vol 5, No 3 (2004) | Farmacoeconomia e outcomes research | Abstract PDF |
| Ermanno Attanasio | ||
| Vol 5, No 4 (2004) | Farmacoeconomia ed etica: cure sostenibili e rispetto della persona | Abstract PDF |
| Antonio G. Spagnolo, Roberta Minacori | ||
| Vol 4, No 1S (2003) | Farmacoepidemiologia e farmacoeconomia della terapia anti-ipertensiva: uno studio osservazionale della popolazione della Asl di Ravenna | Abstract PDF |
| Luca Degli Esposti, Alessandro Capone, Mirko Di Martino, Stefania Saragoni, Samuele Berlini, Pierluigi Russo, Ezio Degli Esposti | ||
| Vol 7, No 3 (2006) | First drug utilization data related to an anticholinergic agent recently marketed in Italy | Abstract PDF |
| Carlo Lucioni, S. Mazzi, C. Cerra, S. Lottaroli | ||
| Vol 14, No 2 (2013) | First-line HIV treatment: evaluation of backbone choice and its budget impact | Abstract HTML PDF |
| Orietta Zaniolo, Massimiliano Povero, Paolo Bonfanti, Marco Borderi, Massimo Medaglia | ||
| Vol 4, No 3 (2003) | Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico | Abstract PDF |
| Carlo Della Pepa, Mario Eandi | ||
| Vol 2, No 3 (2001) | Fluvoxamina: profilo farmacoeconomico | Abstract PDF |
| Mario Eandi | ||
| Vol 6, No 3 (2005) | Forme galeniche e qualità di vita: il caso di tramadolo | Abstract PDF |
| Orietta Zaniolo | ||
| Vol 9, No 1S (2008) | Friuli Venezia Giulia | Abstract PDF |
| Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi | ||
| Vol 13, No 2S (2012) | Friuli-Venezia Giulia | Abstract HTML PDF |
| Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni | ||
| Vol 13, No 3S (2012) | From generic to biosimilar drugs: why take an innovative pace? | Abstract HTML PDF |
| Fereshteh Barei, Claude Le Pen, Steven Simoens | ||
| Vol 21, No 1 (2020) | Funding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy | Abstract HTML PDF |
| Massimiliano Povero, Lorenzo Pradelli | ||
| Vol 11, No 2 (2010) | Fungal infections today: size of the problem and focus on the initial cost of therapy with echinocandin | Abstract PDF |
| Mario Venditti | ||
| Vol 12, No 2 (2011) | Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+ | Abstract HTML PDF |
| Viola Sacchi | ||
| Vol 13, No 3S (2012) | Generic and biosimilar medicines: quid? | Abstract HTML PDF |
| Steven Simoens | ||
| Vol 6, No 4 (2005) | Gli antagonisti del recettore GPIIb/IIIa: farmacologia, clinica ed economia nelle sindromi coronariche acute NSTEMI e nelle rivascolarizzazioni per via percutanea | Abstract PDF |
| Lorenzo Pradelli | ||
| Vol 4, No 1 (2003) | Gli inibitori della pompa protonica nelle patologie acido correlate: il ruolo di rabeprazolo in una strategia di cost-minimisation | Abstract PDF |
| Giorgio L. Colombo, Andrea Muzio | ||
| Vol 2, No 4 (2001) | Gli studi di “cost of illness” in Italia: una review della letteratura | Abstract |
| Andrea Bracco | ||
| Vol 15, No 1 (2014) | GOLD guidelines adherence impact on the NHS budget | Abstract HTML PDF |
| Alessandro Guasconi, Claudio Ripellino, Franca Heiman | ||
| Vol 9, No 4 (2008) | Growing impact of pharmacogenomic on drug development and personalized medicine | Details PDF |
| Mario Eandi | ||
| Vol 12, No 2S (2011) | Health Technology Assessment | Details PDF |
| Lorenzo G. Mantovani, Giuseppe La Torre, Giancarlo Cesana, Walter Ricciardi | ||
| Vol 22, No 1S (2021) | Health Technology Assessment on the use of the Wearable Cardioverter Defibrillator in Patients with Myocardial Infarction and with ICD Explant | Abstract HTML PDF |
| Paolo Angelo Cortesi, Giovanni Luca Botto, Lucia D'Angiolella, Luciana Scalone, Roberto De Ponti, Giuseppe Boriani, Lorenzo Giovanni Mantovani | ||
| Vol 19, No 1 (2018) | Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units | Abstract HTML PDF |
| Valentina Perrone, Diego Sangiorgi, Stefano Buda, Margherita Andretta, Silvio Borrè, Chiara Cattaruzzi, Gina Gasperini, Fabio Lena, Alessia Pisterna, Luca Degli Esposti | ||
| Vol 16, No 1 (2015) | Hospital Based Health Technology Assessment: an example from Siena | Abstract HTML PDF |
| Pietro Manzi, Pietro Barberini, Fabrizio Dori | ||
| Vol 16, No 1 (2015) | Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation | Details HTML PDF |
| Mihajlo Jakovljevic, Marko Folic, Aleksandar Dagovic | ||
| 101 - 200 of 477 Items | << < 1 2 3 4 5 > >> | |
User
Font Size